Antisense oligonucleotides against the lipid phosphatase SHIP2 improve muscle insulin sensitivity in a dietary rat model of the metabolic syndrome - PubMed (original) (raw)
. 2007 Jun;292(6):E1871-8.
doi: 10.1152/ajpendo.00263.2006. Epub 2007 Feb 27.
Affiliations
- PMID: 17327370
- DOI: 10.1152/ajpendo.00263.2006
Free article
Antisense oligonucleotides against the lipid phosphatase SHIP2 improve muscle insulin sensitivity in a dietary rat model of the metabolic syndrome
Roland Buettner et al. Am J Physiol Endocrinol Metab. 2007 Jun.
Free article
Abstract
The lipid phosphatase SH2 domain-containing lipid phosphatase (SHIP2) has been implicated in the regulation of insulin sensitivity, but its role in the therapy of insulin-resistant states remains to be defined. Here, we examined the effects of an antisense oligonucleotide (AS) therapy directed against SHIP2 on whole body insulin sensitivity and insulin action in liver and muscle tissue in a dietary rodent model of the metabolic syndrome, the high-fat-fed (HF) rat. Whole body insulin sensitivity was examined in vivo by insulin tolerance tests before and after the intraperitoneal application of an AS directed against SHIP2 (HF-SHIP2-AS) or a control AS (HF-Con-AS) in HF rats. Insulin action in liver and muscle was assayed by measuring the activation of protein kinase B (Akt) and insulin receptor substrate (IRS)-1/2 after a portal venous insulin bolus. SHIP2 mRNA and protein content were quantified in these tissues by real-time PCR and immunoblotting, respectively. In HF-SHIP2-AS, whole body glucose disposal after an insulin bolus was markedly elevated compared with HF-Con-AS. In liver, insulin activated Akt similarly in both groups. In muscle, insulin did not clearly activate Akt in HF-Con-AS animals, whereas insulin-induced Akt phosphorylation was sustained in SHIP2-AS-treated rats. IRS-1/2 activation did not differ between the experimental groups. SHIP2 mRNA and protein content were markedly reduced only in muscle. In standard diet-fed controls, SHIP2-AS reduced SHIP2 protein levels in liver and muscle, but it had no significant effect on insulin sensitivity. We conclude that treatment with SHIP2-AS can rapidly improve muscle insulin sensitivity in dietary insulin resistance. The long-term feasibility of such a strategy should be examined further.
Similar articles
- Reversal of denervation-induced insulin resistance by SHIP2 protein synthesis blockade.
Bertelli DF, Ueno M, Amaral ME, Toyama MH, Carneiro EM, Marangoni S, Carvalho CR, Saad MJ, Velloso LA, Boschero AC. Bertelli DF, et al. Am J Physiol Endocrinol Metab. 2003 Apr;284(4):E679-87. doi: 10.1152/ajpendo.00345.2002. Epub 2002 Nov 26. Am J Physiol Endocrinol Metab. 2003. PMID: 12453826 - SH2-containing inositol phosphatase 2 negatively regulates insulin-induced glycogen synthesis in L6 myotubes.
Sasaoka T, Hori H, Wada T, Ishiki M, Haruta T, Ishihara H, Kobayashi M. Sasaoka T, et al. Diabetologia. 2001 Oct;44(10):1258-67. doi: 10.1007/s001250100645. Diabetologia. 2001. PMID: 11692174 - Impact of lipid phosphatases SHIP2 and PTEN on the time- and Akt-isoform-specific amelioration of TNF-alpha-induced insulin resistance in 3T3-L1 adipocytes.
Ikubo M, Wada T, Fukui K, Ishiki M, Ishihara H, Asano T, Tsuneki H, Sasaoka T. Ikubo M, et al. Am J Physiol Endocrinol Metab. 2009 Jan;296(1):E157-64. doi: 10.1152/ajpendo.90581.2008. Epub 2008 Nov 11. Am J Physiol Endocrinol Metab. 2009. PMID: 19001549 - Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity.
Sasaoka T, Wada T, Tsuneki H. Sasaoka T, et al. Pharmacol Ther. 2006 Dec;112(3):799-809. doi: 10.1016/j.pharmthera.2006.06.001. Epub 2006 Jul 13. Pharmacol Ther. 2006. PMID: 16842857 Review. - The SH2 domain containing inositol polyphosphate 5-phosphatase-2: SHIP2.
Dyson JM, Kong AM, Wiradjaja F, Astle MV, Gurung R, Mitchell CA. Dyson JM, et al. Int J Biochem Cell Biol. 2005 Nov;37(11):2260-5. doi: 10.1016/j.biocel.2005.05.003. Int J Biochem Cell Biol. 2005. PMID: 15964236 Review.
Cited by
- Discovery and development of small molecule SHIP phosphatase modulators.
Viernes DR, Choi LB, Kerr WG, Chisholm JD. Viernes DR, et al. Med Res Rev. 2014 Jul;34(4):795-824. doi: 10.1002/med.21305. Epub 2013 Dec 2. Med Res Rev. 2014. PMID: 24302498 Free PMC article. Review. - PI3K/SHIP2/PTEN pathway in cell polarity and hepatitis C virus pathogenesis.
Awad A, Gassama-Diagne A. Awad A, et al. World J Hepatol. 2017 Jan 8;9(1):18-29. doi: 10.4254/wjh.v9.i1.18. World J Hepatol. 2017. PMID: 28105255 Free PMC article. Review. - Regulation of MAP kinase-directed mitogenic and protein kinase B-mediated signaling by cannabinoid receptor type 1 in skeletal muscle cells.
Lipina C, Stretton C, Hastings S, Hundal JS, Mackie K, Irving AJ, Hundal HS. Lipina C, et al. Diabetes. 2010 Feb;59(2):375-85. doi: 10.2337/db09-0979. Epub 2009 Nov 23. Diabetes. 2010. PMID: 19933999 Free PMC article. Retracted. - Biochemical and cellular properties of insulin receptor signalling.
Haeusler RA, McGraw TE, Accili D. Haeusler RA, et al. Nat Rev Mol Cell Biol. 2018 Jan;19(1):31-44. doi: 10.1038/nrm.2017.89. Epub 2017 Oct 4. Nat Rev Mol Cell Biol. 2018. PMID: 28974775 Free PMC article. Review. - Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2.
Suwa A, Yamamoto T, Sawada A, Minoura K, Hosogai N, Tahara A, Kurama T, Shimokawa T, Aramori I. Suwa A, et al. Br J Pharmacol. 2009 Oct;158(3):879-87. doi: 10.1111/j.1476-5381.2009.00358.x. Epub 2009 Aug 19. Br J Pharmacol. 2009. PMID: 19694723 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous